TSE:TR Trillium Therapeutics (TR) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free TR Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,075 shsAverage Volume99,071 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Trillium Therapeutics alerts: Email Address Ad Weiss RatingsMassive Crisis Looming — Protect Your Savings NowToday, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom.Click here to learn how to prepare before it's too late. About Trillium Therapeutics Stock (TSE:TR)Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.Read More Ad Weiss RatingsMassive Crisis Looming — Protect Your Savings NowToday, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom.Click here to learn how to prepare before it's too late. TR Stock News HeadlinesMay 28, 2024 | msn.comKabete National Polytechnic Ranked Best TTI in New Timely Kenya SurveyMay 28, 2024 | theglobeandmail.comPension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest fundsMay 7, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, OncologyMay 6, 2024 | finance.yahoo.comRatio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating OfficerApril 15, 2024 | finance.yahoo.comSezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura BioApril 2, 2024 | finance.yahoo.comUpstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership TeamMarch 12, 2024 | finance.yahoo.comRatio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted RadiopharmaceuticalsJanuary 17, 2024 | bizjournals.comRatio Therapeutics raises $50M for tumor-targeting radiopharmaceuticalsJune 22, 2023 | finance.yahoo.comTvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 InhibitorJune 20, 2023 | benzinga.comPD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsightMay 9, 2023 | finance.yahoo.comRatio Therapeutics Announces Opening of New Research and Development FacilityApril 25, 2023 | finance.yahoo.comTrillium Engineering Announces Its Latest Innovation in Cameras Utilizing AI Technology - HD80-AIMMarch 10, 2023 | msn.comWho's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In PersonFebruary 6, 2023 | finanznachrichten.deViridian Therapeutics, Inc: Viridian Appoints Scott Myers as President and Chief Executive OfficerJanuary 28, 2023 | detroitnews.comTaylor Trillium building into Division 4 state power, behind coach Terrell GeorgeDecember 19, 2022 | benzinga.comLeiomyosarcoma Drug Pipeline Research Report 2022: Comprehensive Insights on 18+ Companies and 18+ Pipeline DrugsDecember 6, 2022 | finance.yahoo.comRatio Therapeutics Appoints Reed Malleck as Chief Financial OfficerNovember 3, 2022 | seekingalpha.comPfizer: Q3 Earnings Review - Planning For Life After COVIDAugust 8, 2022 | msn.comCash-rich Pfizer snaps up Global Blood Therapeutics for $5.4 billionMay 22, 2022 | seekingalpha.comPfizer: Management's M&A Activity Is Winning Me OverMay 18, 2022 | finanznachrichten.deThiogenesis Therapeutics, Corp.: Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102May 18, 2022 | stockhouse.comThiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102May 14, 2022 | msn.com3 Dirt-Cheap Stocks You Can Buy Right NowMay 10, 2022 | baystreet.caPfizer Buys Biohaven for $11.6BFebruary 17, 2022 | morningstar.comNeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioSee More Headlines Receive TR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolTSE:TR CUSIPN/A CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesCalvin R. Stiller M.D.Independent Chairman of the BoardNiclas StiernholmPresident, Chief Executive Officer, DirectorJames T. ParsonsChief Financial OfficerMalik SlassiSenior Vice President - Discovery ResearchRobert UgerChief Scientific OfficerScott DuncanDirector of Intellectual PropertyPenka PetrovaChief Development OfficerEric L SieversChief Medical OfficerLuke M. Beshar CPA (Age 59)Independent Director Henry Friesen M.D. (Age 79)Independent Director More Executives TR Stock Analysis - Frequently Asked Questions Is Trillium Therapeutics a good dividend stock? Trillium Therapeutics (TSE:TR) pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), ConocoPhillips (COP), Canadian Natural Resources (CNQ), bluebird bio (BLUE) and Biogen (BIIB). How do I buy shares of Trillium Therapeutics? Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TR) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | Sponsored41 banks launch ‘crypto dollar’Everyone knows the US financial system is in the middle of a radical change... The White House wants an all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.